Hussman Strategic Advisors, Inc. Nurix Therapeutics, Inc. Put Options Transaction History
Hussman Strategic Advisors, Inc.
- $384 Million
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding NRIX
# of Institutions
181Shares Held
74.4MCall Options Held
56.9KPut Options Held
7.9K-
Black Rock Inc. New York, NY6.82MShares$85.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$68.8 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$55.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$50.6 Million5.06% of portfolio
-
Commodore Capital LP New York, NY3.98MShares$49.7 Million4.63% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $589M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...